BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C.
Cohen M, et al. Among authors: zephir h.
Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30.
Mult Scler. 2021.
PMID: 33124504